New malaria vaccine trial aims to protect women and their future babies
NCT ID NCT06080243
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the R21/Matrix-M1 malaria vaccine in 330 healthy women aged 18–35 in Mali who may become pregnant. Participants receive two or three doses of the vaccine or a placebo, and are followed for two years to check safety, immune response, and protection against malaria. Pregnant women and their babies are also monitored for safety and infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- R21/Matrix-M1 malaria vaccine
- What this could lead to
- If successful, this vaccine could help protect women of childbearing age from malaria, reducing infection and improving maternal and child health in malaria-endemic regions.
- What could go wrong
- This is a phase II trial with only 330 participants, so results may not apply to larger populations. The vaccine may not provide lasting protection or could have side effects not yet seen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY WOMEN OF CHILD BEARING POTENTIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Koumantou Study Clinic
Bougouni, Sikasso, Mali
More trials for these conditions
Other studies related to the condition(s) this trial covers.